Health News

A two-drug combination destroys precancerous colon polyps with no effect on normal tissue, opening a new potential avenue for chemoprevention of colon cancer, a team of scientists at The University of Texas M. D. Anderson Cancer Center reports in the advance online edition of the journal Nature.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Online, Pharmacy

Related posts

• When To Administer Food And Drugs Together (0)
  A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing. In a commentary published early online Sept. 19 in the Journal of Clinical Oncology, Ratain, the Leon [...]
  
  
• Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion (0)
  Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal PLoS ONE. Read more [tags] Pharmacy News [/tags]
  
  
• Project Zero Delay Accelerates Drug’s Path To Clinical Trial (0)
  A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their [...]
  
  
• Preclinical data of Curis’ HSP 90 inhibitor published (0)
  Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics. Read more [tags] Pharmacy News [/tags]
  
  
• Phase III studies should make meaningful difference in patients’ quality of life: Commentary (0)
  Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in The Journal of the National Cancer Institute. Read more [tags] Pharmacy News [/tags]